WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaREGULATORY MATTERS
Ver el documentoAMIODARONE - Medication Guide to be dispensed along with medicine
Ver el documentoATOMOXETINE - Labelling to include liver injury warning
Ver el documentoBENZATHINE BENZYL-PENICILLIN/PROCAINEBENZYLPENICILLIN - Label changes highlight appropriate use
Ver el documentoMEFLOQUINE - Patient Information Leaflet to help recognize adverse symptoms
Ver el documentoPARACETAMOL-DEXTROPROP-OXYPHENE - To be withdrawn due to risk of toxicity in overdose
Ver el documentoSMALLPOX VACCINE - Label to highlight reports of myopericarditis
Ver el documentoTHIORIDAZINE - Withdrawn due to poor benefit/risk profile
Abrir esta carpeta y ver su contenidoSAFETY OF MEDICINES
Abrir esta carpeta y ver su contenidoDRUGS OF CURRENT INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

ATOMOXETINE - Labelling to include liver injury warning

USA. The US FDA has issued a Talk Paper advising of changes to the US atomoxetine (Strattera) labelling, following two reports of severe liver injury in patients who had received the agent for several months. Atomoxetine is a selective norepinephrine reuptake inhibitor indicated in the treatment of attention deficit hyperactive disorder (ADHD) in children, adolescents and adults. The atomoxetine labelling is to be updated to include a bolded warning regarding the risk of severe liver injury that could progress to liver failure, requiring liver transplantation or resulting in death, although it is noted that the actual number of cases is unknown. The new warning advises discontinuation of atomoxetine if patients develop jaundice or laboratory evidence of liver injury. Eli Lilly has agreed to issue a 'Dear Healthcare Professional' letter regarding these changes, and will update the atomoxetine patient package insert to include information about the signs and symptoms of liver disorders.

Reference:

FDA Talk Paper, 17 December 2004. Available on the Internet at www.fda.gov

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018